Recently, AIM announced a comprehensive deployment to integrate the DeepSeek large model, particularly in vaccine development ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

the mRNA shingles vaccine and the mRNA RSV vaccine. In just one month, AIM has leveraged its independently innovated mRNA technology platform to deliver two major products, both of which have received ...

Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Britain's drugs regulator has today approved an mRNA vaccine to protect the over 60s against respiratory syncytial virus (RSV). Results of the treatment, developed by US pharmaceutical giant ...

With AI support, AIM is expected to rapidly advance multiple key products, including the mRNA shingles vaccine, mRNA RSV vaccine, and mRNA influenza vaccine. Previously, the research report from Fosun ...

designed to protect against RSV and COVID-19. Beyond vaccines, pharma is looking to develop mRNA vaccines to treat diseases requiring protein expression, such as cancer. Cancer has proved to be a ...

PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S.